Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Val-mCyd Dose Escalation in Chronic Hepatitis C
NCT00227435Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2003
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valopicitabine in hepatitis C (HCV), sponsored by Merck & Co.. Started Feb 2003; status: completed.
02
Drugs
valopicitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00227435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227435.